Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Coxsackie B virus.
Marjomäki V, Flodström-Tullberg M. Marjomäki V, et al. Trends Microbiol. 2022 Jun;30(6):606-607. doi: 10.1016/j.tim.2022.01.016. Epub 2022 Feb 16. Trends Microbiol. 2022. PMID: 35183399 No abstract available.
A novel rat CVB1-VP1 monoclonal antibody 3A6 detects a broad range of enteroviruses.
Saarinen NVV, Laiho JE, Richardson SJ, Zeissler M, Stone VM, Marjomäki V, Kantoluoto T, Horwitz MS, Sioofy-Khojine A, Honkimaa A, Hankaniemi MM, Flodström-Tullberg M, Hyöty H, Hytönen VP, Laitinen OH. Saarinen NVV, et al. Among authors: marjomaki v. Sci Rep. 2018 Jan 8;8(1):33. doi: 10.1038/s41598-017-18495-4. Sci Rep. 2018. PMID: 29311608 Free PMC article.
A Common Receptor Found for Echoviruses.
Laajala M, Marjomäki V. Laajala M, et al. Among authors: marjomaki v. Trends Microbiol. 2019 Jun;27(6):475-477. doi: 10.1016/j.tim.2019.03.010. Epub 2019 Apr 16. Trends Microbiol. 2019. PMID: 31003872
A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine.
Hankaniemi MM, Stone VM, Sioofy-Khojine AB, Heinimäki S, Marjomäki V, Hyöty H, Blazevic V, Laitinen OH, Flodström-Tullberg M, Hytönen VP. Hankaniemi MM, et al. Among authors: marjomaki v. Vaccine. 2019 Sep 20;37(40):5962-5971. doi: 10.1016/j.vaccine.2019.08.037. Epub 2019 Aug 27. Vaccine. 2019. PMID: 31471148 Free article.
Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine.
Hankaniemi MM, Stone VM, Andrejeff T, Heinimäki S, Sioofy-Khojine AB, Marjomäki V, Hyöty H, Blazevic V, Flodström-Tullberg M, Hytönen VP, Laitinen OH. Hankaniemi MM, et al. Among authors: marjomaki v. Antiviral Res. 2019 Nov;171:104595. doi: 10.1016/j.antiviral.2019.104595. Epub 2019 Sep 3. Antiviral Res. 2019. PMID: 31491431 Free article.
A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates.
Stone VM, Hankaniemi MM, Laitinen OH, Sioofy-Khojine AB, Lin A, Diaz Lozano IM, Mazur MA, Marjomäki V, Loré K, Hyöty H, Hytönen VP, Flodström-Tullberg M. Stone VM, et al. Among authors: marjomaki v. Sci Adv. 2020 May 6;6(19):eaaz2433. doi: 10.1126/sciadv.aaz2433. eCollection 2020 May. Sci Adv. 2020. PMID: 32494709 Free PMC article.
Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine.
Hankaniemi MM, Baikoghli MA, Stone VM, Xing L, Väätäinen O, Soppela S, Sioofy-Khojine A, Saarinen NVV, Ou T, Anson B, Hyöty H, Marjomäki V, Flodström-Tullberg M, Cheng RH, Hytönen VP, Laitinen OH. Hankaniemi MM, et al. Among authors: marjomaki v. Microorganisms. 2020 Aug 24;8(9):1287. doi: 10.3390/microorganisms8091287. Microorganisms. 2020. PMID: 32846899 Free PMC article.
115 results